机译:基于索非布韦的方案在基因 2 型慢性丙型肝炎感染患者中并不理想:来自 HEPATHER ANRS CO22 队列的真实经验
Bordeaux Univ, Hepatol Unit, Univ Hosp Bordeaux, Pessac, France;
Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM, Paris, France;
Lorraine Univ, Hepatogastoenterol, Univ Hosp Nancy, Nancy, FranceLyon Univ, Hepatol Dept, Hosp Civils Lyon, Lyon, FranceCHU Montpellier, Liver Unit, St Eloi Hosp, Montpellier, FranceCHU Toulouse, Serv Hepatol Rangeuil, Toulouse, FranceUniv Cote dAzur, Nice, FranceUniv Paris, Beaujon Hosp, AP HP, Hepatol Unit,Inserm UMR 1149, Clichy, FranceAP HP Paul Brousse, Hepatol Unit, Villejuif, FranceSorbonne Univ, St Antoine Hosp, AP HP, Hepatol Dept,INSERM,St Antoine Res Ctr, Paris, FranceUniv Paris Est, Hop Henri Mondor, Dept Virol, Natl Reference Ctr Viral Hepatitis B C & DeltaAP HP Cochin, Hepatol Unit, Paris, France;
daclatasvir; direct-acting antivirals; genotype 2; HEPATHER; Hepatitis C; real-world; sofosbuvir;